Global Director, Health Economics and Outcomes Research (HEOR)

Company Overview

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early stage ADCs pursuing undisclosed solid tumor targets.

Position Overview

Immunome is seeking a highly experienced and strategic Global Director, Health Economics and Outcomes Research (HEOR) to lead the global (US and OUS) value and outcomes evidence strategy for our oncology portfolio, including preparing for the potential imminent launch of varegacestat as well as supporting the extensive ADC pipeline. This role will be accountable for developing and executing HEOR, real-world evidence (RWE), and patient-reported outcomes (PRO/COA) plans across the product lifecycle - from early development through launch and ongoing lifecycle management.

The successful candidate will bring deep expertise in health economic modeling, outcomes research, and PRO/COA strategy, along with proven launch experience and the leadership skills necessary to partner across Clinical Development, Medical Affairs, and Global Market Access & Pricing. This position offers a highly visible opportunity to shape Immunome’s value evidence strategy and enable broad patient access to our innovative oncology therapies.

Responsibilities

Strategic Leadership

• Develop and lead the global HEOR strategy and integrated evidence generation plans (HEOR, RWE, and PRO/COA) aligned to asset strategy, TPP, and global market access needs across key geographies.
• Provide scientific leadership on PRO/COA endpoint strategy, including instrument selection, endpoint positioning, analysis considerations, and interpretation to support differentiation, publications, and potential labeling claims.
• Lead development, collaboration, and governance of economic value tools (e.g., cost-effectiveness models, budget impact models, value dossiers, and payer value messaging) to support pre-launch planning and launch readiness.

Program Oversight and Execution

• Partner with Clinical Development, Biostatistics, Clinical Operations, and Medical Affairs to integrate HEOR/RWE and PRO/COA endpoints into clinical trials and to define analysis plans and interpretation.
• Design and oversee outcomes and RWE studies (e.g., observational studies, registries, claims/EHR analyses, ITCs, and meta-analyses) to support epidemiology, comparative effectiveness, and post-launch commitments.
• Lead cross-functional development and execution of global launch deliverables (e.g., global value dossier, US AMCP dossier as applicable, HTA submissions/briefings, and payer evidence packages) within established timelines and quality expectations.

Vendor and Partner Management

• Identify, qualify, and manage global HEOR, RWE, and PRO/COA vendors and consulting partners to ensure timely, high-quality, and compliant delivery of evidence and access-enabling deliverables.
• Oversee scope, budget, and performance for external partners; establish clear deliverables, governance, and quality control processes to meet Immunome standards.

Regulatory and Documentation Support

• Contribute to clinical development and regulatory strategy by providing HEOR and PRO/COA input to protocols, statistical analysis plans, briefing documents, and select sections of submissions as appropriate.
• Lead responses to payer and HTA evidence requests and support external stakeholder engagements (HTA bodies, payers, IDNs) in collaboration with Market Access and Medical Affairs.
• Ensure HEOR, RWE, and PRO/COA activities adhere to applicable standards and guidance (e.g., ISPOR good practices, FDA PRO guidance, relevant privacy requirements, and quality expectations).

Leadership and Collaboration

• Serve as the primary HEOR and PRO/COA subject matter expert on cross-functional global program teams; translate complex evidence into clear, actionable recommendations for senior leadership.
• Mentor and develop internal capabilities and contribute to building scalable processes for integrated evidence planning, model governance, and publication planning.
• Collaborate closely with Global Market Access, Pricing, Commercial, Medical Affairs, Biostatistics, Epidemiology, and Regulatory functions to align evidence strategy with launch and lifecycle objectives.

Qualifications

• PhD in Health Economics, Outcomes Research, Public Health, Epidemiology, Health Services Research, or related field or a medical degree (e.g. PharmD/MD) with a post-doctoral fellowship or master’s degree in Health Economics, Outcomes Research, Public Health, Epidemiology, Health Services Research, or related field with 5+ years of experience
• Proven global product launch experience, including development of value dossiers and HTA/payer evidence packages supporting pricing, reimbursement, and formulary access decisions.
• Deep expertise in patient-reported outcomes (PRO) / clinical outcome assessments (COA), including endpoint strategy, instrument selection, data interpretation, and vendor oversight (ePRO/COA providers). Experience with regulatory agency interactions (Type B/C/D meetings and/or NDA filings).
• Demonstrated experience developing health economic models (cost-effectiveness, budget impact) and payer value communication tools; advanced Excel modeling proficiency and familiarity with R or other analytics tools are a plus.
• Strong understanding of global market access and HTA requirements across major markets (e.g., US payer landscape/AMCP, NICE, CADTH, G-BA/IQWiG, HAS, AIFA).
• Experience designing and overseeing RWE and outcomes studies using secondary data (claims, EHR, registries) and evidence synthesis approaches (systematic literature reviews, meta-analyses, ITCs).
• Oncology drug development experience preferred; experience in rare disease and/or specialty products a plus.

Knowledge and Skills

• Expert knowledge of HEOR and RWE methodologies, including economic evaluation, comparative effectiveness research, and outcomes study design.
• Strong working knowledge of PRO/COA standards and guidance (e.g., FDA PRO guidance; ISPOR and ISOQOL good practices) and experience working with COA vendors and ePRO platforms.
• Ability to lead integrated evidence planning and translate payer/HTA evidence needs into executable study plans and high-impact deliverables for launch and lifecycle management.
• Excellent communication skills - able to clearly convey complex economic and outcomes concepts to technical and non-technical stakeholders.
• Demonstrated success managing external vendors and budgets and delivering high-quality outputs on tight timelines.
• Proven leadership and influence in a matrix environment; capable of driving alignment and decision-making across functions and geographies.
• Strong publication and scientific communication skills, including development of abstracts, manuscripts, congress materials, and internal evidence narratives.
• Highly organized, analytical, and solutions-oriented; able to manage multiple priorities in a fast-paced, dynamic biotech environment.

E/E/O

Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.

E-Verify

Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish).